Tuberculosis multidrogorresistente

La tuberculosis (TB) es la enfermedad bacteriana infecciosa que más muertes causa en el mundo, panorama que puede empeorar debido a la drogorresistencia. La tuberculosis multidrogoresistente (TB-MDR), es decir la que presenta resistencia simultánea a isoniazida y rifampicina (principales fármacos an...

Full description

Autores:
Urrego-Díaz, José Augusto
Tipo de recurso:
https://purl.org/coar/resource_type/c_6501
Fecha de publicación:
2020
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
spa
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/5832
Acceso en línea:
https://hdl.handle.net/20.500.12495/5832
https://doi.org/10.18270/rsb.v10i1.2834
Palabra clave:
Tuberculosis
Infección
Farmacorresistencia Microbiana
Quimioterapia
Agentes Antibuberculosos
Tuberculosis
Infection
Multidrug-Resistant
Treatment
Antitubercular Agents
Rights
License
Atribución-NoComercial-CompartirIgual 4.0 Internacional
id UNBOSQUE2_7a7a344b51b88d09e4beb7688812e70b
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/5832
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv Tuberculosis multidrogorresistente
dc.title.translated.spa.fl_str_mv Multidrug-resistant tuberculosis
title Tuberculosis multidrogorresistente
spellingShingle Tuberculosis multidrogorresistente
Tuberculosis
Infección
Farmacorresistencia Microbiana
Quimioterapia
Agentes Antibuberculosos
Tuberculosis
Infection
Multidrug-Resistant
Treatment
Antitubercular Agents
title_short Tuberculosis multidrogorresistente
title_full Tuberculosis multidrogorresistente
title_fullStr Tuberculosis multidrogorresistente
title_full_unstemmed Tuberculosis multidrogorresistente
title_sort Tuberculosis multidrogorresistente
dc.creator.fl_str_mv Urrego-Díaz, José Augusto
dc.contributor.author.none.fl_str_mv Urrego-Díaz, José Augusto
dc.contributor.orcid.none.fl_str_mv Urrego-Díaz, José Augusto[0000-0002-5234-2112]
dc.subject.spa.fl_str_mv Tuberculosis
Infección
Farmacorresistencia Microbiana
Quimioterapia
Agentes Antibuberculosos
topic Tuberculosis
Infección
Farmacorresistencia Microbiana
Quimioterapia
Agentes Antibuberculosos
Tuberculosis
Infection
Multidrug-Resistant
Treatment
Antitubercular Agents
dc.subject.keywords.spa.fl_str_mv Tuberculosis
Infection
Multidrug-Resistant
Treatment
Antitubercular Agents
description La tuberculosis (TB) es la enfermedad bacteriana infecciosa que más muertes causa en el mundo, panorama que puede empeorar debido a la drogorresistencia. La tuberculosis multidrogoresistente (TB-MDR), es decir la que presenta resistencia simultánea a isoniazida y rifampicina (principales fármacos antituberculosos), tiene una relevancia particular: de los 10 mi-llones de personas que desarrollan TB anualmente, 458.000 presentan TB-MDR con un pronóstico mucho peor que el de los infectados por cepas sensibles. En el presente artículo se exploran los principales aspectos de la TB-MDR, haciendo énfasis en su tratamiento
publishDate 2020
dc.date.issued.none.fl_str_mv 2020-07-22
dc.date.accessioned.none.fl_str_mv 2021-05-06T14:04:59Z
dc.date.available.none.fl_str_mv 2021-05-06T14:04:59Z
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.local.spa.fl_str_mv Artículo de revista
dc.type.coar.none.fl_str_mv https://purl.org/coar/resource_type/c_6501
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
dc.type.coarversion.none.fl_str_mv https://purl.org/coar/version/c_970fb48d4fbd8a85
format https://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv 2322-9462
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12495/5832
dc.identifier.doi.none.fl_str_mv https://doi.org/10.18270/rsb.v10i1.2834
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv repourl:https://repositorio.unbosque.edu.co
identifier_str_mv 2322-9462
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
repourl:https://repositorio.unbosque.edu.co
url https://hdl.handle.net/20.500.12495/5832
https://doi.org/10.18270/rsb.v10i1.2834
dc.language.iso.none.fl_str_mv spa
language spa
dc.relation.ispartofseries.spa.fl_str_mv Rev. salud. bosque /ISSN 2322-946 / Volumen 10 /ene. - jun . de 2020 / Número 1/ Págs. 80-8
dc.relation.uri.none.fl_str_mv https://revistasaludbosque.unbosque.edu.co/index.php/RSB/article/view/2834
dc.relation.references.spa.fl_str_mv Murray PR, Rosenthal KS, Pfaller MA. Mycobacterium. En: Microbiología médica. 6ta ed. Barcelona: Elsevier España; 2009.
Kumar V, Abbas AK, Fausto N, Aster JC. Micobacterias. En: Robbins y Cotran: Patología estructural y funcional. 8va ed. Barcelona: Elsevier España; 2010.
World Health Organization (WHO). Global tuberculosis report 2019. Geneva: WHO; 2019.
Raviglione MC. Tuberculosis. En: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editores. Ha-rrison: Principios de medicina interna. 18va ed. New York: McGraw-Hill; 2012
Colombia. Instituto Nacional de Salud (INS). Informe de evento: Tuberculosis, Colombia, 2017. Bogotá, D.C.: INS; 2018.
Houben RM, Dodd PJ. The Global Burden of Latent Tuber-culosis Infection: A Re-estimation Using Mathematical Mo-delling. PLoS Med. 2016;13(10):e1002152. DOI: 10.1371/journal.pmed.1002152
Organización Panamericana de la Salud (OPS). Tuberculosis en las Américas 2018. Washington, D.C.: OPS; 2018.
Colombia. Instituto Nacional de Salud (INS). Boletín Epi-demiológico Semanal. Semana epidemiológica 38. Bogotá D.C.: INS; 2018
Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tu-berculosis. Lancet. 2010;375(9728):1830-43. DOI: 10.1016/S0140 - 6736(10)60410 -2
Daley CL, Caminero JA. Management of Multidrug-Resistant Tuberculosis. Semin Respir Crit Care Med. 2018;39(3):310 -24. DOI: 10.1055/s- 0038 -1661383
Colombia. Ministerio de Salud y Protección Social (MinSalud). Circular externa 55 de 2016 (diciembre 20): Actualización DE los lineamientos para el manejo progra-mático de tuberculosis en niños, casos farmacoresistentes y aspectos de la programación de sintomáticos respirato-rios. Bogota D.C.: MinSalud; 2016
Centers for Disease Control and Prevention (CDC). Core Curriculum on Tuberculosis: What the Clinician Should Know. 6ta ed. CDC; 2013
Colombia. Ministerio de Salud y Protección Social, Institu-to Nacional de Salud. Lineamientos para el manejo progra-mático de pacientes con tuberculosis farmacorresistente. Bogotá D.C.: MinSalud; 2013
Garzón MC, Angée DY, Llerena C, Orjuela DL, Victoria JE. Vigilancia de la resistencia del Mycobacterium tuberculo-sis a los fármacos antituberculosos, Colombia 2004-2005. Biomédica. 2008:28(3):319-26. DOI: 10.7705/biomedica.v28i3.71
Mak A, Thomas A, Del Granado M, Zaleskis R, Mouza-farova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized re-gimens. Am J Respir Crit Care Med. 2008;178(3):306-12. DOI: 10.1164/rccm.200802-240OC
Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149(2):123-34. DOI: 10.7326/0003-4819-149-2-200807150-0000
World Health Organization (WHO). Global tuberculosis report 2017. Geneva: WHO; 2017
Colombia. Instituto Nacional de Salud (INS). Informe de actividades realizadas por la Red Nacional de Laborato-rios para la vigilancia de la resistencia de Mycobacterium tuberculosis a los fármacos Antituberculosos, Colombia 2013. Bogotá D.C.: INS; 2014.
Colombia. Instituto Nacional de Salud (INS). Protocolo de vigilancia en salud pública: Tuberculosis farmacoresisten-te. Bogotá, D.C.: INS; 2017
World Health Organization (WHO). Treatment of tubercu-losis: guidelines for national programmes. Geneva: WHO; 2003. WHO
World Health Organization (WHO). Global tuberculosis report 2016. Geneva: WHO; 2016.
Centers for Disease Control and Prevention (CDC). Labora-tory User Guide for U.S. Public Health Laboratories: Mole-cular Detection of Drug Resistance (MDDR) in Mycobac-terium tuberculosis Complex by DNA Sequencing (Version 2.0), June 2012. Atlanta: CDC; 2012 [citado 2019 sep 14]. Disponible en: https://www.cdc.gov/tb/topic/laboratory/mddrusersguide.pdf
Telenti A. Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax. 1998;53(9):793-7. DOI: 10.1136/thx.53.9.793.
Fontalvo-Rivera D, Gómez-Camargo D. Genes del Myco-bacterium tuberculosis involucrados en la patogenicidad y resistencia a antibióticos durante la tuberculosis pulmonar y extrapulmonar. Medicas UIS. 2015;28(1):39-51.
Sacchettini JC, Blanchard JS. The structure and function of the isoniazid target in M. tuberculosis. Res Microbiol. 1996;147(1-2):36-43. DOI: 10.1016/0923-2508(96)80201-4
Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacte-rium tuberculosis. Nature. 1992;358(6387):591-3. DOI: 10.1038/358591a0
Heym B, Alzari PM, Honoré N, Cole ST. Missense muta-tions in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol. 1995;15(2):235-45. DOI: 10.1111/j.1365-2958.1995.tb02238.x
Cockerill FR, Uhl JR, Temesgen Z, Zhang Y, Stockman L, Roberts GD, et al. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis. 1995;171(1):240 -5. DOI: 10.1093/ infdis /171.1.240
Brennan PJ, Nikaido H. The envelope of mycobacteria. An-nu Rev Biochem. 1995;64:29-63. DOI: 10.1146/annurev.bi.64.070195.000333
Rozwarski DA, Grant GA, Barton DH, Jacobs WR, Sa-cchettini JC. Modification of the NADH of the isonia-zid target (InhA) from Mycobacterium tuberculosis. Science. 1998;279(5347):98-102. DOI: 10.1126/scien-ce.279.5347.98
Bloom BR. Tuberculosis: Pathogenesis, Protection, and Control. Washington DC: ASM Press; 1994
Miller LP, Crawford JT, Shinnick TM. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Che-mother. 1994;38(4):805-11. DOI: 10.1128/aac.38.4.805
Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647-50. DOI: 10.1016/0140-6736(93)90417-f.
Cole ST. Rifamycin resistance in mycobacteria. Res Microbiol. 1996;147(1-2):48-52. DOI: 10.1016/0923-2508(96)80203-8
World Health Organization (WHO). Consolidated guide-lines on drug-resistant tuberculosis treatment. Geneva: WHO; 2019.
World Health Organization (WHO). WHO Treatment Gui-delines for Drug-Resistant Tuberculosis: 2016 Update. Ge-neva: WHO; 2016.
Colombia. Ministerio de Salud y Protección Social. Linea-mientos técnicos y operativos del programa nacional de tuberculosis [documento en consulta interna]. Bogotá: MinSalud; 2019.38
World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: WHO; 2011.
World Health Organization (WHO). The Use of bedaqui-line in the Treatment of MultidrugResistant Tuberculosis: Interim Policy Guidance. Geneva: WHO; 2013
World Health Organization (WHO). The Use of delamanid in the Treatment of MultidrugResistant Tuberculosis: Inte-rim Policy Guidance. Geneva: WHO; 2014
World Health Organization (WHO). The use of delamanid in the treatment of multidrug-resistant tuberculosis in chil-dren and adolescents: interim policy guidance. Geneva: WHO; 2016
World Health Organization (WHO). The use of delamanid in the treatment of multidrug-resistant tuberculosis in chil-dren and adolescents: interim policy guidance. Geneva: WHO; 2016
World Health Organization (WHO). Guidelines for the treatment of drug-susceptible tuberculosis and patient ca-re: 2017 update. Geneva: WHO; 2017
World Health Organization (WHO). WHO treatment gui-delines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tubercu-losis. Geneva: WHO; 2018
World Health Organization. WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis: 2018 update. Geneva: WHO; 2018.
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Socie-ty/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e95. DOI: 10.1093/cid/ciw376.
Curry International Tuberculosis Center. Drug-Resistant Tu-berculosis: A Survival Guide for Clinicians. 3ra ed. Wash-ington D.C.; CITC; 2016
World Health Organization (WHO). Rapid communica-tion: key changes to treatment of multidrug- and rifampi-cin-resistant tuberculosis (TB-MDR/RR). Geneva: WHO; 2019 [citado 2019 sep 20]. Disponible en: https://www.who.int/tb/publications/2019/WHO_RapidCommunica-tionMDRTB2019.pdf?ua=1.
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019;380(13):1201-13. DOI: 10.1056 / NEJM oa1811867.
Deltyba (delamanid). Amsterdam: European Medicines Agency; 2018 [citado 2019 sep 27]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba
Sirturo (bedaquiline). Amsterdam: European Medicines Agency; 2014. [citado 2019 sep 27]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo
World Health Organization (WHO). WHO best-practice statement on the off-label use of bedaquiline and delama-nid for the treatment of multidrug-resistant tuberculosis. Geneva: WHO; 2017 [citado 2019 sep 27]. Disponible en: https://apps.who.int/iris/bitstream/10665/258941/1/WHO-HTM-TB-2017.20-eng.pdf
Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive stan-dardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684-92. DOI: 10.1164/rccm.201001-0077OC
Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A. High effectiveness of a 12-month regimen for TB-MDR patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517-24. DOI: 10.5588/ijtld.14.0535.
Piubello A, Harouna SH, Souleymane MB, Boukary I, Mo-rou S, Daouda M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18(10):1188-94. DOI: 10.5588/ijtld.13.0075.
Ahmad-Khan F, Salim MAH, du Cros P, Casas EC, Kha-mraev A, Sikhondze W, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate da-ta meta-analyses. Eur Respir J. 2017;50(1):1700061. DOI: 10.1183/13993003.00061-2017.
World Health Organization (WHO). Position Statement on the Continued Use of the Shorter TB-MDR Regimen fo-llowing an Expedited Review of the STREAM Stage 1 Preli-minary Results. Geneva: WHO; 2018
Moodley R, Godec TR, Team ST. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Res-pir Rev. 2016;25(139):29-35. : 10.1183/16000617.0080-2015
Caminero JA, Caylac JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnóstico y tratamien-to de la tuberculosis con resistencia a fármacos. Arch Bronconeumol. 2017;53(9):501-9. DOI: 10.1016/j.ar-bres.2017.02.006
Caminero JA, Caylac JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnóstico y tratamien-to de la tuberculosis con resistencia a fármacos. Arch Bronconeumol. 2017;53(9):501-9. DOI: 10.1016/j.ar-bres.2017.02.006
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculo-sis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. DOI: 10.1371/journal.pmed.1001300.
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculo-sis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. DOI: 10.1371/journal.pmed.1001300.
Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, An-derson LF, Baghaei P, et al. Treatment correlates of suc-cessful outcomes in pulmonary multidrug-resistant tu-berculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821-34. DOI: 10.1016/S0140-6736(18)316 4 4 -1
Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018;15(7):e10 02591. DOI: 10.1371/journal.pmed.10 02591.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Ba-lanag V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-con-trolled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249-59. DOI: 10.1016/S2213-2600(18)30426-0.
Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug re-sistant tuberculosis: a retrospective cohort study. Clin Infect Dis. 2018 ;68(9):1522-1529. DOI: 10.1093/cid/ciy727
Borisov SE, Dheda K, Enwerem M, Romero-Leyet R, D’Ambrosio L, Centis R, et al. Effectiveness and safe-ty of bedaquiline-containing regimens in the treatment of MDR- and XTB-DR: a multicentre study. Eur Respir J. 2017;49(5):1700387. DOI: 10.1183/13993003.00387-2017.
Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retros-pective cohort study. Lancet Respir Med. 2018;6(9):699-706. DOI: 10.1016/S2213-2600(18)30235-2.
Diacon AH, Pym A, Grobusch MP, de los Rios JM, Go-tuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723-32. DOI: 10.1056 / NEJM oa1313865
Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397- 405. DOI: 10.1056/NEJMoa0808427
Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Che-mother. 2012;56(6):3271-6. DOI: 10.1128/AAC.06126-11
Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;3(3):CD012836. DOI: 10.1002/14651858.CD012836.pub2.
Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for mul-tidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188(7):858-64. DOI: 10.1164/rccm.201303-0604OC.
dc.rights.*.fl_str_mv Atribución-NoComercial-CompartirIgual 4.0 Internacional
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv https://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Atribución-NoComercial-CompartirIgual 4.0 Internacional
https://creativecommons.org/licenses/by-nc-sa/4.0/
Acceso abierto
https://purl.org/coar/access_right/c_abf2
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.journal.spa.fl_str_mv Revista Salud Bosque
institution Universidad El Bosque
bitstream.url.fl_str_mv https://pruebas-update-repositorio-unbosque.cloudbiteca.com/bitstreams/41002769-784e-420f-9227-a280e6d799c1/download
https://pruebas-update-repositorio-unbosque.cloudbiteca.com/bitstreams/187c173d-01c1-4b8c-afca-14fe123f7072/download
https://pruebas-update-repositorio-unbosque.cloudbiteca.com/bitstreams/18dc50f7-424d-46ed-96cb-62b31514d381/download
https://pruebas-update-repositorio-unbosque.cloudbiteca.com/bitstreams/a1d742a5-b3bb-49c2-8e51-184739b5806b/download
bitstream.checksum.fl_str_mv fa3a3ff48a85e891f20aded428e1410a
934f4ca17e109e0a05eaeaba504d7ce4
8a4605be74aa9ea9d79846c1fba20a33
fd2d0b7c3530c00d848d335e03ee892a
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad El Bosque
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1849967205829050368
spelling Urrego-Díaz, José AugustoUrrego-Díaz, José Augusto[0000-0002-5234-2112]2021-05-06T14:04:59Z2021-05-06T14:04:59Z2020-07-222322-9462https://hdl.handle.net/20.500.12495/5832https://doi.org/10.18270/rsb.v10i1.2834instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coLa tuberculosis (TB) es la enfermedad bacteriana infecciosa que más muertes causa en el mundo, panorama que puede empeorar debido a la drogorresistencia. La tuberculosis multidrogoresistente (TB-MDR), es decir la que presenta resistencia simultánea a isoniazida y rifampicina (principales fármacos antituberculosos), tiene una relevancia particular: de los 10 mi-llones de personas que desarrollan TB anualmente, 458.000 presentan TB-MDR con un pronóstico mucho peor que el de los infectados por cepas sensibles. En el presente artículo se exploran los principales aspectos de la TB-MDR, haciendo énfasis en su tratamientoTuberculosis (TB) is the worldwide leading infectious cause of death and, the emergence of drug-resistant tuberculosis can only worsen the scenario. Multidrug-Resistant Tuberculosis (TB-MDR) has proven resistant to both isoniazid and rifampin, the main antituberculous drugs. Out of 10 million people developing TB annually, 458 000 exhibit TB-MDR, having worse prognosis than those infected by sensitive strains. Recently, new drug-re-sistant TB treatment guidelines were issued both by the World Health Or-ganization and health authorities in Colombia. The present paper explores the main aspects of TB-MDR emphasizing s sanitary authorities also, new guidelines were published by Colombian minister of health and social pro-tection. In this paper, the main aspects of TB-MDR are explored, especially those related to its treatment.application/pdfspaRev. salud. bosque /ISSN 2322-946 / Volumen 10 /ene. - jun . de 2020 / Número 1/ Págs. 80-8https://revistasaludbosque.unbosque.edu.co/index.php/RSB/article/view/2834Murray PR, Rosenthal KS, Pfaller MA. Mycobacterium. En: Microbiología médica. 6ta ed. Barcelona: Elsevier España; 2009.Kumar V, Abbas AK, Fausto N, Aster JC. Micobacterias. En: Robbins y Cotran: Patología estructural y funcional. 8va ed. Barcelona: Elsevier España; 2010.World Health Organization (WHO). Global tuberculosis report 2019. Geneva: WHO; 2019.Raviglione MC. Tuberculosis. En: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editores. Ha-rrison: Principios de medicina interna. 18va ed. New York: McGraw-Hill; 2012Colombia. Instituto Nacional de Salud (INS). Informe de evento: Tuberculosis, Colombia, 2017. Bogotá, D.C.: INS; 2018.Houben RM, Dodd PJ. The Global Burden of Latent Tuber-culosis Infection: A Re-estimation Using Mathematical Mo-delling. PLoS Med. 2016;13(10):e1002152. DOI: 10.1371/journal.pmed.1002152Organización Panamericana de la Salud (OPS). Tuberculosis en las Américas 2018. Washington, D.C.: OPS; 2018.Colombia. Instituto Nacional de Salud (INS). Boletín Epi-demiológico Semanal. Semana epidemiológica 38. Bogotá D.C.: INS; 2018Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tu-berculosis. Lancet. 2010;375(9728):1830-43. DOI: 10.1016/S0140 - 6736(10)60410 -2Daley CL, Caminero JA. Management of Multidrug-Resistant Tuberculosis. Semin Respir Crit Care Med. 2018;39(3):310 -24. DOI: 10.1055/s- 0038 -1661383Colombia. Ministerio de Salud y Protección Social (MinSalud). Circular externa 55 de 2016 (diciembre 20): Actualización DE los lineamientos para el manejo progra-mático de tuberculosis en niños, casos farmacoresistentes y aspectos de la programación de sintomáticos respirato-rios. Bogota D.C.: MinSalud; 2016Centers for Disease Control and Prevention (CDC). Core Curriculum on Tuberculosis: What the Clinician Should Know. 6ta ed. CDC; 2013Colombia. Ministerio de Salud y Protección Social, Institu-to Nacional de Salud. Lineamientos para el manejo progra-mático de pacientes con tuberculosis farmacorresistente. Bogotá D.C.: MinSalud; 2013Garzón MC, Angée DY, Llerena C, Orjuela DL, Victoria JE. Vigilancia de la resistencia del Mycobacterium tuberculo-sis a los fármacos antituberculosos, Colombia 2004-2005. Biomédica. 2008:28(3):319-26. DOI: 10.7705/biomedica.v28i3.71Mak A, Thomas A, Del Granado M, Zaleskis R, Mouza-farova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized re-gimens. Am J Respir Crit Care Med. 2008;178(3):306-12. DOI: 10.1164/rccm.200802-240OCLew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149(2):123-34. DOI: 10.7326/0003-4819-149-2-200807150-0000World Health Organization (WHO). Global tuberculosis report 2017. Geneva: WHO; 2017Colombia. Instituto Nacional de Salud (INS). Informe de actividades realizadas por la Red Nacional de Laborato-rios para la vigilancia de la resistencia de Mycobacterium tuberculosis a los fármacos Antituberculosos, Colombia 2013. Bogotá D.C.: INS; 2014.Colombia. Instituto Nacional de Salud (INS). Protocolo de vigilancia en salud pública: Tuberculosis farmacoresisten-te. Bogotá, D.C.: INS; 2017World Health Organization (WHO). Treatment of tubercu-losis: guidelines for national programmes. Geneva: WHO; 2003. WHOWorld Health Organization (WHO). Global tuberculosis report 2016. Geneva: WHO; 2016.Centers for Disease Control and Prevention (CDC). Labora-tory User Guide for U.S. Public Health Laboratories: Mole-cular Detection of Drug Resistance (MDDR) in Mycobac-terium tuberculosis Complex by DNA Sequencing (Version 2.0), June 2012. Atlanta: CDC; 2012 [citado 2019 sep 14]. Disponible en: https://www.cdc.gov/tb/topic/laboratory/mddrusersguide.pdfTelenti A. Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax. 1998;53(9):793-7. DOI: 10.1136/thx.53.9.793.Fontalvo-Rivera D, Gómez-Camargo D. Genes del Myco-bacterium tuberculosis involucrados en la patogenicidad y resistencia a antibióticos durante la tuberculosis pulmonar y extrapulmonar. Medicas UIS. 2015;28(1):39-51.Sacchettini JC, Blanchard JS. The structure and function of the isoniazid target in M. tuberculosis. Res Microbiol. 1996;147(1-2):36-43. DOI: 10.1016/0923-2508(96)80201-4Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacte-rium tuberculosis. Nature. 1992;358(6387):591-3. DOI: 10.1038/358591a0Heym B, Alzari PM, Honoré N, Cole ST. Missense muta-tions in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol. 1995;15(2):235-45. DOI: 10.1111/j.1365-2958.1995.tb02238.xCockerill FR, Uhl JR, Temesgen Z, Zhang Y, Stockman L, Roberts GD, et al. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis. 1995;171(1):240 -5. DOI: 10.1093/ infdis /171.1.240Brennan PJ, Nikaido H. The envelope of mycobacteria. An-nu Rev Biochem. 1995;64:29-63. DOI: 10.1146/annurev.bi.64.070195.000333Rozwarski DA, Grant GA, Barton DH, Jacobs WR, Sa-cchettini JC. Modification of the NADH of the isonia-zid target (InhA) from Mycobacterium tuberculosis. Science. 1998;279(5347):98-102. DOI: 10.1126/scien-ce.279.5347.98Bloom BR. Tuberculosis: Pathogenesis, Protection, and Control. Washington DC: ASM Press; 1994Miller LP, Crawford JT, Shinnick TM. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Che-mother. 1994;38(4):805-11. DOI: 10.1128/aac.38.4.805Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647-50. DOI: 10.1016/0140-6736(93)90417-f.Cole ST. Rifamycin resistance in mycobacteria. Res Microbiol. 1996;147(1-2):48-52. DOI: 10.1016/0923-2508(96)80203-8World Health Organization (WHO). Consolidated guide-lines on drug-resistant tuberculosis treatment. Geneva: WHO; 2019.World Health Organization (WHO). WHO Treatment Gui-delines for Drug-Resistant Tuberculosis: 2016 Update. Ge-neva: WHO; 2016.Colombia. Ministerio de Salud y Protección Social. Linea-mientos técnicos y operativos del programa nacional de tuberculosis [documento en consulta interna]. Bogotá: MinSalud; 2019.38World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: WHO; 2011.World Health Organization (WHO). The Use of bedaqui-line in the Treatment of MultidrugResistant Tuberculosis: Interim Policy Guidance. Geneva: WHO; 2013World Health Organization (WHO). The Use of delamanid in the Treatment of MultidrugResistant Tuberculosis: Inte-rim Policy Guidance. Geneva: WHO; 2014World Health Organization (WHO). The use of delamanid in the treatment of multidrug-resistant tuberculosis in chil-dren and adolescents: interim policy guidance. Geneva: WHO; 2016World Health Organization (WHO). The use of delamanid in the treatment of multidrug-resistant tuberculosis in chil-dren and adolescents: interim policy guidance. Geneva: WHO; 2016World Health Organization (WHO). Guidelines for the treatment of drug-susceptible tuberculosis and patient ca-re: 2017 update. Geneva: WHO; 2017World Health Organization (WHO). WHO treatment gui-delines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tubercu-losis. Geneva: WHO; 2018World Health Organization. WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis: 2018 update. Geneva: WHO; 2018.Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Socie-ty/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e95. DOI: 10.1093/cid/ciw376.Curry International Tuberculosis Center. Drug-Resistant Tu-berculosis: A Survival Guide for Clinicians. 3ra ed. Wash-ington D.C.; CITC; 2016World Health Organization (WHO). Rapid communica-tion: key changes to treatment of multidrug- and rifampi-cin-resistant tuberculosis (TB-MDR/RR). Geneva: WHO; 2019 [citado 2019 sep 20]. Disponible en: https://www.who.int/tb/publications/2019/WHO_RapidCommunica-tionMDRTB2019.pdf?ua=1.Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019;380(13):1201-13. DOI: 10.1056 / NEJM oa1811867.Deltyba (delamanid). Amsterdam: European Medicines Agency; 2018 [citado 2019 sep 27]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/deltybaSirturo (bedaquiline). Amsterdam: European Medicines Agency; 2014. [citado 2019 sep 27]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/sirturoWorld Health Organization (WHO). WHO best-practice statement on the off-label use of bedaquiline and delama-nid for the treatment of multidrug-resistant tuberculosis. Geneva: WHO; 2017 [citado 2019 sep 27]. Disponible en: https://apps.who.int/iris/bitstream/10665/258941/1/WHO-HTM-TB-2017.20-eng.pdfVan Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive stan-dardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684-92. DOI: 10.1164/rccm.201001-0077OCKuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A. High effectiveness of a 12-month regimen for TB-MDR patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517-24. DOI: 10.5588/ijtld.14.0535.Piubello A, Harouna SH, Souleymane MB, Boukary I, Mo-rou S, Daouda M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18(10):1188-94. DOI: 10.5588/ijtld.13.0075.Ahmad-Khan F, Salim MAH, du Cros P, Casas EC, Kha-mraev A, Sikhondze W, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate da-ta meta-analyses. Eur Respir J. 2017;50(1):1700061. DOI: 10.1183/13993003.00061-2017.World Health Organization (WHO). Position Statement on the Continued Use of the Shorter TB-MDR Regimen fo-llowing an Expedited Review of the STREAM Stage 1 Preli-minary Results. Geneva: WHO; 2018Moodley R, Godec TR, Team ST. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Res-pir Rev. 2016;25(139):29-35. : 10.1183/16000617.0080-2015Caminero JA, Caylac JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnóstico y tratamien-to de la tuberculosis con resistencia a fármacos. Arch Bronconeumol. 2017;53(9):501-9. DOI: 10.1016/j.ar-bres.2017.02.006Caminero JA, Caylac JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnóstico y tratamien-to de la tuberculosis con resistencia a fármacos. Arch Bronconeumol. 2017;53(9):501-9. DOI: 10.1016/j.ar-bres.2017.02.006Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculo-sis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. DOI: 10.1371/journal.pmed.1001300.Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculo-sis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. DOI: 10.1371/journal.pmed.1001300.Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, An-derson LF, Baghaei P, et al. Treatment correlates of suc-cessful outcomes in pulmonary multidrug-resistant tu-berculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821-34. DOI: 10.1016/S0140-6736(18)316 4 4 -1Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018;15(7):e10 02591. DOI: 10.1371/journal.pmed.10 02591.von Groote-Bidlingmaier F, Patientia R, Sanchez E, Ba-lanag V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-con-trolled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249-59. DOI: 10.1016/S2213-2600(18)30426-0.Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug re-sistant tuberculosis: a retrospective cohort study. Clin Infect Dis. 2018 ;68(9):1522-1529. DOI: 10.1093/cid/ciy727Borisov SE, Dheda K, Enwerem M, Romero-Leyet R, D’Ambrosio L, Centis R, et al. Effectiveness and safe-ty of bedaquiline-containing regimens in the treatment of MDR- and XTB-DR: a multicentre study. Eur Respir J. 2017;49(5):1700387. DOI: 10.1183/13993003.00387-2017.Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retros-pective cohort study. Lancet Respir Med. 2018;6(9):699-706. DOI: 10.1016/S2213-2600(18)30235-2.Diacon AH, Pym A, Grobusch MP, de los Rios JM, Go-tuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723-32. DOI: 10.1056 / NEJM oa1313865Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397- 405. DOI: 10.1056/NEJMoa0808427Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Che-mother. 2012;56(6):3271-6. DOI: 10.1128/AAC.06126-11Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;3(3):CD012836. DOI: 10.1002/14651858.CD012836.pub2.Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for mul-tidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188(7):858-64. DOI: 10.1164/rccm.201303-0604OC.Atribución-NoComercial-CompartirIgual 4.0 Internacionalhttps://creativecommons.org/licenses/by-nc-sa/4.0/Acceso abiertohttps://purl.org/coar/access_right/c_abf2http://purl.org/coar/access_right/c_abf2TuberculosisInfecciónFarmacorresistencia MicrobianaQuimioterapiaAgentes AntibuberculososTuberculosisInfectionMultidrug-ResistantTreatmentAntitubercular AgentsTuberculosis multidrogorresistenteMultidrug-resistant tuberculosisArtículo de revistahttps://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttps://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/version/c_970fb48d4fbd8a85Revista Salud BosqueORIGINALPORTADA1.pngPORTADA1.pngimage/png3332705https://pruebas-update-repositorio-unbosque.cloudbiteca.com/bitstreams/41002769-784e-420f-9227-a280e6d799c1/downloadfa3a3ff48a85e891f20aded428e1410aMD51trueAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81031https://pruebas-update-repositorio-unbosque.cloudbiteca.com/bitstreams/187c173d-01c1-4b8c-afca-14fe123f7072/download934f4ca17e109e0a05eaeaba504d7ce4MD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://pruebas-update-repositorio-unbosque.cloudbiteca.com/bitstreams/18dc50f7-424d-46ed-96cb-62b31514d381/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADTHUMBNAILPORTADA1.png.jpgPORTADA1.png.jpgIM Thumbnailimage/jpeg10157https://pruebas-update-repositorio-unbosque.cloudbiteca.com/bitstreams/a1d742a5-b3bb-49c2-8e51-184739b5806b/downloadfd2d0b7c3530c00d848d335e03ee892aMD54falseAnonymousREAD20.500.12495/5832oai:pruebas-update-repositorio-unbosque.cloudbiteca.com:20.500.12495/58322021-08-18T21:02:00.489Zhttps://creativecommons.org/licenses/by-nc-sa/4.0/Atribución-NoComercial-CompartirIgual 4.0 Internacionalopen.accesshttps://pruebas-update-repositorio-unbosque.cloudbiteca.comRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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

Publicaciones similares